A 65-year-old woman with familial hypercholesterolemia (heterozygous) and prior myocardial infarction is on atorvastatin 80 mg daily. Her LDL cholesterol remains 120 mg/dL despite maximum statin dose. Which agent should be added to achieve LDL target <70 mg/dL?

Explanation

## Management of Statin-Inadequate LDL Control **Key Point:** When LDL targets are not achieved on maximum-dose statin therapy, PCSK9 inhibitors are the preferred add-on agent, especially in secondary prevention (prior MI) and familial hypercholesterolemia [cite:Harrison 21e Ch 395]. ### Why PCSK9 Inhibitor is Optimal 1. **Potent LDL Reduction:** PCSK9 inhibitors achieve 50–60% additional LDL reduction when added to statin, bringing LDL from 120 to ~50–60 mg/dL. 2. **Cardiovascular Outcomes:** PCSK9 inhibitors (evolocumab, alirocumab) have demonstrated MACE reduction in secondary prevention trials (FOURIER, ODYSSEY OUTCOMES). 3. **Familial Hypercholesterolemia:** Indicated specifically for heterozygous familial hypercholesterolemia inadequately controlled on statins. 4. **Safety Profile:** Well-tolerated; no significant drug interactions or organ toxicity concerns. ### Comparison of Statin Add-On Agents | Agent | Class | LDL ↓ (Additional) | Mechanism | MACE Benefit | Use | |-------|-------|---|---|---|---| | **PCSK9i (Evolocumab)** | Monoclonal Ab | 50–60% | ↑ LDL receptor | Yes (proven) | First-line add-on | | **Ezetimibe** | Cholesterol absorption inhibitor | 15–20% | Block NPC1L1 | Modest | Weak; consider if PCSK9i unavailable | | **Bempedoic acid** | Uricosuric AMPK activator | 15–20% | ↓ Uric acid, mild LDL ↓ | Emerging | Adjunct, gout benefit | | **Nicotinic acid** | B vitamin | 15–25% | ↓ VLDL synthesis | Uncertain | GI side effects, flushing; less used | | **Bile acid sequestrants** | Resin | 15–30% | ↑ Fecal cholesterol loss | No | Weak, GI burden; outdated | | **Fibrates** | PPAR-α agonist | Minimal LDL | ↓ TG, ↑ HDL | No for LDL | Wrong phenotype; TG-focused | **High-Yield:** PCSK9 inhibitors are the only class with proven MACE reduction in secondary prevention when added to statins; they are guideline-recommended for statin-inadequate LDL control in high-risk patients. **Mnemonic:** **PCSK9 = Proprotein Convertase Subtilisin/Kexin type 9** — blocks the enzyme that degrades LDL receptors, allowing more LDL uptake. **Clinical Pearl:** In a 65-year-old post-MI patient with familial hypercholesterolemia and LDL 120 on max statin, PCSK9 inhibitor is guideline-mandated to achieve LDL <70 mg/dL (secondary prevention target). **Warning:** Do not confuse PCSK9 inhibitors with other add-ons — ezetimibe alone is insufficient (only 15–20% reduction); nicotinic acid has fallen out of favor due to side effects and uncertain MACE benefit; fibrates are wrong for LDL-focused therapy.